MA31699B1 - Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 - Google Patents

Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3

Info

Publication number
MA31699B1
MA31699B1 MA32688A MA32688A MA31699B1 MA 31699 B1 MA31699 B1 MA 31699B1 MA 32688 A MA32688 A MA 32688A MA 32688 A MA32688 A MA 32688A MA 31699 B1 MA31699 B1 MA 31699B1
Authority
MA
Morocco
Prior art keywords
histamine
isokinolinil
isoendolinil
receptors
derivatives
Prior art date
Application number
MA32688A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Dahui Zhou
Jonathan Laird Gross
Albert Jean Robichaud
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MA31699B1 publication Critical patent/MA31699B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA32688A 2007-09-12 2010-03-12 Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 MA31699B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99363607P 2007-09-12 2007-09-12
PCT/US2008/075981 WO2009036144A1 (en) 2007-09-12 2008-09-11 Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists

Publications (1)

Publication Number Publication Date
MA31699B1 true MA31699B1 (fr) 2010-09-01

Family

ID=40261509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32688A MA31699B1 (fr) 2007-09-12 2010-03-12 Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3

Country Status (25)

Country Link
US (1) US20090069300A1 (OSRAM)
EP (1) EP2200989A1 (OSRAM)
JP (1) JP2010539180A (OSRAM)
KR (1) KR20100054856A (OSRAM)
CN (1) CN101848896A (OSRAM)
AP (1) AP2010005202A0 (OSRAM)
AR (1) AR068423A1 (OSRAM)
AU (1) AU2008298926A1 (OSRAM)
BR (1) BRPI0817061A2 (OSRAM)
CA (1) CA2699384A1 (OSRAM)
CL (1) CL2008002726A1 (OSRAM)
CO (1) CO6300955A2 (OSRAM)
CR (1) CR11303A (OSRAM)
DO (1) DOP2010000079A (OSRAM)
EA (1) EA201000316A1 (OSRAM)
EC (1) ECSP10010025A (OSRAM)
MA (1) MA31699B1 (OSRAM)
MX (1) MX2010002760A (OSRAM)
NI (1) NI201000036A (OSRAM)
PA (1) PA8795701A1 (OSRAM)
PE (1) PE20090651A1 (OSRAM)
TN (1) TN2010000105A1 (OSRAM)
TW (1) TW200927114A (OSRAM)
WO (1) WO2009036144A1 (OSRAM)
ZA (1) ZA201001751B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EA026385B9 (ru) 2010-07-02 2017-08-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
WO2012058133A1 (en) * 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Isoindolinone pde10 inhibitors
CN105693645B (zh) * 2011-05-10 2018-10-09 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
US9173395B2 (en) 2011-07-04 2015-11-03 Bayer Intellectual Property Gmbh Use of substituted isoquinolinones, isoquinolindiones, isoquinolintriones and dihydroisoquinolinones or in each case salts thereof as active agents against abiotic stress in plants
WO2013076590A1 (en) 2011-11-23 2013-05-30 Oxygen Healthcare Research Pvt. Ltd Benzothiazine compounds as h3 receptor ligands
CN105254554B (zh) * 2014-07-14 2018-01-30 南开大学 一种制备异吲哚啉酮类化合物的方法
WO2021207554A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CA3191279A1 (en) * 2020-08-28 2022-03-03 Yi Liu Heterocyclic compounds and uses thereof
US12496297B1 (en) * 2020-10-23 2025-12-16 Washington University Compositions of autophagy modulating agents and uses thereof
CN115819347B (zh) * 2022-11-14 2024-08-30 暨明医药科技(苏州)有限公司 一种1-烷基-3-溴吡唑的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US4166853A (en) * 1978-05-05 1979-09-04 The Upjohn Company Antihypertensive 7-trifluoromethyl-4-aminoquinolones
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
WO1998048800A1 (en) * 1997-05-01 1998-11-05 Eli Lilly And Company Antithrombotic agents
CA2441080A1 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
ES2305491T3 (es) * 2002-09-19 2008-11-01 Eli Lilly And Company Eteres de diarilo como antagonistas de receptores de opioides.
DE602005003951T4 (de) * 2004-05-14 2012-10-11 Millennium Pharmaceuticals, Inc. Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US20060014733A1 (en) * 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
CN101107231A (zh) * 2005-01-21 2008-01-16 先灵公司 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物
EP1877401A2 (en) * 2005-04-15 2008-01-16 Elan Pharmaceuticals Inc. Novel compounds useful for bradykinin b1 receptor antagonism

Also Published As

Publication number Publication date
AP2010005202A0 (en) 2010-04-30
ZA201001751B (en) 2010-11-24
TN2010000105A1 (fr) 2011-09-26
JP2010539180A (ja) 2010-12-16
EA201000316A1 (ru) 2010-10-29
BRPI0817061A2 (pt) 2015-03-24
US20090069300A1 (en) 2009-03-12
NI201000036A (es) 2010-08-13
CN101848896A (zh) 2010-09-29
AU2008298926A1 (en) 2009-03-19
PA8795701A1 (es) 2009-04-23
MX2010002760A (es) 2010-04-01
AR068423A1 (es) 2009-11-18
TW200927114A (en) 2009-07-01
EP2200989A1 (en) 2010-06-30
DOP2010000079A (es) 2010-03-31
ECSP10010025A (es) 2010-08-31
PE20090651A1 (es) 2009-05-28
CL2008002726A1 (es) 2008-10-10
WO2009036144A1 (en) 2009-03-19
KR20100054856A (ko) 2010-05-25
CA2699384A1 (en) 2009-03-19
CR11303A (es) 2010-03-18
CO6300955A2 (es) 2011-07-21

Similar Documents

Publication Publication Date Title
MA31699B1 (fr) Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3
MA31700B1 (fr) Derives d'azacyclylisoquinolinone et -isoindolinone servant d'antagonistes du recepteur d'histamine-3
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
WO2007136668A3 (en) N-benzoyl-and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
CO6190517A2 (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
MA33492B1 (fr) Inhibiteurs de bace
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
MA33559B1 (fr) Composes bicycliques 5,6- heteroaryle contenant l'uree comme inhibiteurs de kinase.
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MA38315A1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
EA200900783A1 (ru) Соединения и композиции в качестве ингибиторов киназы